Who Paid My Doc
A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Eva
Research payments
$1,257,651
Through program year 2023, $1,257,651 in research payments was reported against A Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Eva, across 354 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $205,448 | 48 |
| 2022 | Research | $1,052,203 | 306 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Merlin Fausett Missoula, MT Named on 40 payments
- Guy Middleton Dothan, AL Named on 39 payments
- Stephen Stamatis Weatherford, TX Named on 34 payments
- Scott Striplin Hammond, LA Named on 30 payments
- Blake Landry Slidell, LA Named on 24 payments
- Dawnette Peppler Arlington, TX Named on 21 payments
- Charles Rogers Grove Hill, AL Named on 14 payments
- John Roberts Plano, TX Named on 14 payments
- Darrell Robinson Lafayette, LA Named on 13 payments
- Charles Sharp Birmingham, AL Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.